Guggenheim Maintains Buy on Sagimet Biosciences, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 62.0%

Neg 62% Neu 0% Pos 0%

Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $27 to $25.